Skip to main content

Table 1 Baseline characteristics of 23 patients with Chlamydia trachomatis and Neisseria gonorrhoeae coinfection at inclusion

From: Time to clearance of Chlamydia trachomatis RNA and DNA after treatment in patients coinfected with Neisseria gonorrhoeae – a prospective cohort study

Characteristics Total
N (%)a
Urethra
N (%)a
Rectum
N (%)a
Endocervix
N (%)a
P
Total 23 7 (30.4) 7 (30.4) 9 (39.1)  
Gender
  Male 14 (60.9) 7 (100.0) 7 (100.0) 0 (0.0)  
  Female 9 (39.1) 0 (0.0) 0 (0.0) 9 (100.0)  
Median age, in years (IQR) 24 (20–35) 29 (24–35) 40 (24–44) 20 (19–23) 0.003
Ethnicity      1.00
  Dutch 11 (47.8) 3 (42.9) 4 (57.1) 4 (44.4)  
  Non-Dutch 12 (52.2) 4 (57.1) 3 (42.9) 5 (55.6)  
Sexual risk group
  MSM 10 (43.5) 3 (42.9) 7 (100.0) 0 (0.0)  
  Hetero male 4 (17.4) 4 (57.1) 0 (0.0) 0 (0.0)  
  Female 9 (39.1) 0 (0.0) 0 (0.0) 9 (100.0)  
HIV positive 5 (21.7) 1 (14.3) 4 (57.1) 0 (0.0) 0.02
  Using cART 4 (80.0) 0 (0.0) 4 (100.0) - 0.20
  CD4+ cell count (cells/mm3)      1.00
    350–499 1 (20.0) 0 (0.0) 1 (25.0) -  
    ≥ 500 4 (80.0) 1 (100.0) 3 (75.0) -  
Previous chlamydia episode 12 (52.2) 3 (42.9) 4 (57.1) 5 (55.6) 1.00
Chlamydia in preceding 6 months 3 (13.0) 0 (0.0) 1 (14.3) 2 (22.2) 0.75
Symptoms or signs at examinationb,c 13 (56.5) 6 (85.7) 3 (42.9) 4 (44.4) 0.23
Median time to inclusion, days (IQR) 8 (0–12) 0 (0–0) 10 (7–13) 9 (8–12) 0.003
Treatment at inclusiond      0.001
Ceftriaxone + azithromycin 16 (69.6) 7 (100.0) 1 (14.3) 8 (88.9)  
Ceftriaxone + doxycycline 7 (30.4) 0 (0.0) 6 (85.7) 1 (11.1)  
  1. IQR interquartile range, MSM men who have sex with men, HIV human immunodeficiency virus, cART combination antiretroviral therapy
  2. aUnless otherwise indicated
  3. bSymptoms included: discharge, itch, burning, frequent or painful urination, bleeding, abdominal pain, pain during sex, anal cramps or pain, and changed defecation
  4. cSigns included: red urethra, discharge, bleeding, fragile mucosa, swelling or anal ulcerations
  5. d1 patient was negative for Chlamydia trachomatis at the initial visit and therefore received ceftriaxone mono-therapy. The test at inclusion was positive and doxycycline was started 6 days after inclusion; therefore the start of the study for the C. trachomatis analysis in this patient was day 6, and the treatment was ceftriaxone + doxycycline